Literature DB >> 22522649

Development of a novel ectonucleotidase assay suitable for high-throughput screening.

Kris F Sachsenmeier1, Carl Hay, Erin Brand, Lori Clarke, Kim Rosenthal, Sandrine Guillard, Steven Rust, Ralph Minter, Robert Hollingsworth.   

Abstract

5'-Ectonucleotidase (NT5E) catalyzes the conversion of adenosine monophosphate to adenosine and free phosphate. The role of this ectonucleotidase and its production of adenosine are linked with immune function, angiogenesis, and cancer. NT5E activity is typically assayed either by chromatographic quantification of substrates and products using high-performance liquid chromatography (HPLC) or by quantification of free phosphate using malachite green. These methods are not suitable for robust screening assays of NT5E activity. HPLC is not readily suitable for the rapid and efficient assay of multiple samples and malachite green is highly sensitive to the phosphate-containing buffers common in various media and sample buffers. Here the development and validation of a novel high-throughput ectonucleotidase screening assay are described, which makes use of a luciferase-based assay reagent, the Promega CellTiter-Glo kit, to measure the catabolism of AMP by NT5E. This multiwell plate-based assay facilitates the screening of potential ectonucleotidase antagonists and is unaffected by the presence of contaminating phosphate molecules present in screening samples.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22522649     DOI: 10.1177/1087057112443987

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  7 in total

1.  CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.

Authors:  Shi Yong Neo; Ying Yang; Julien Record; Ran Ma; Xinsong Chen; Ziqing Chen; Nicholas P Tobin; Emily Blake; Christina Seitz; Ron Thomas; Arnika Kathleen Wagner; John Andersson; Jana de Boniface; Jonas Bergh; Shannon Murray; Evren Alici; Richard Childs; Martin Johansson; Lisa S Westerberg; Felix Haglund; Johan Hartman; Andreas Lundqvist
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

2.  Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.

Authors:  James C Geoghegan; Gundo Diedrich; Xiaojun Lu; Kim Rosenthal; Kris F Sachsenmeier; Herren Wu; William F Dall'Acqua; Melissa M Damschroder
Journal:  MAbs       Date:  2016-02-08       Impact factor: 5.857

3.  Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type.

Authors:  Steven Rust; Sandrine Guillard; Kris Sachsenmeier; Carl Hay; Max Davidson; Anders Karlsson; Roger Karlsson; Erin Brand; David Lowne; John Elvin; Matt Flynn; Gene Kurosawa; Robert Hollingsworth; Lutz Jermutus; Ralph Minter
Journal:  Mol Cancer       Date:  2013-02-13       Impact factor: 27.401

4.  High-throughput screening identifies idarubicin as a preferential inhibitor of smooth muscle versus endothelial cell proliferation.

Authors:  Shakti A Goel; Lian-Wang Guo; Bowen Wang; Song Guo; Drew Roenneburg; Gene E Ananiev; F Michael Hoffmann; K Craig Kent
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

5.  Development, validation and quantitative assessment of an enzymatic assay suitable for small molecule screening and profiling: A case-study.

Authors:  Vicente Sancenon; Wei Hau Goh; Aishwarya Sundaram; Kai Shih Er; Nidhi Johal; Svetlana Mukhina; Grant Carr; Saravanakumar Dhakshinamoorthy
Journal:  Biomol Detect Quantif       Date:  2015-04-27

6.  Targeting CD73 in the tumor microenvironment with MEDI9447.

Authors:  Carl M Hay; Erin Sult; Qihui Huang; Kathy Mulgrew; Stacy R Fuhrmann; Kelly A McGlinchey; Scott A Hammond; Raymond Rothstein; Jonathan Rios-Doria; Edmund Poon; Nick Holoweckyj; Nicholas M Durham; Ching Ching Leow; Gundo Diedrich; Melissa Damschroder; Ronald Herbst; Robert E Hollingsworth; Kris F Sachsenmeier
Journal:  Oncoimmunology       Date:  2016-07-11       Impact factor: 8.110

7.  Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents.

Authors:  Chuanzhen Cao; Xiaomei Lan; Bingqing Shang; Weixing Jiang; Lei Guo; Shan Zheng; Xingang Bi; Aiping Zhou; Zhijian Sun; Jianzhong Shou
Journal:  Clin Transl Oncol       Date:  2022-02-03       Impact factor: 3.340

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.